全文获取类型
收费全文 | 7512篇 |
免费 | 299篇 |
国内免费 | 33篇 |
专业分类
耳鼻咽喉 | 80篇 |
儿科学 | 177篇 |
妇产科学 | 104篇 |
基础医学 | 1119篇 |
口腔科学 | 184篇 |
临床医学 | 375篇 |
内科学 | 2185篇 |
皮肤病学 | 140篇 |
神经病学 | 464篇 |
特种医学 | 262篇 |
外科学 | 1154篇 |
综合类 | 25篇 |
预防医学 | 178篇 |
眼科学 | 80篇 |
药学 | 465篇 |
中国医学 | 22篇 |
肿瘤学 | 830篇 |
出版年
2023年 | 27篇 |
2022年 | 57篇 |
2021年 | 114篇 |
2020年 | 80篇 |
2019年 | 113篇 |
2018年 | 109篇 |
2017年 | 102篇 |
2016年 | 125篇 |
2015年 | 117篇 |
2014年 | 195篇 |
2013年 | 279篇 |
2012年 | 461篇 |
2011年 | 499篇 |
2010年 | 270篇 |
2009年 | 234篇 |
2008年 | 468篇 |
2007年 | 534篇 |
2006年 | 579篇 |
2005年 | 569篇 |
2004年 | 512篇 |
2003年 | 474篇 |
2002年 | 471篇 |
2001年 | 76篇 |
2000年 | 66篇 |
1999年 | 81篇 |
1998年 | 153篇 |
1997年 | 106篇 |
1996年 | 93篇 |
1995年 | 72篇 |
1994年 | 66篇 |
1993年 | 73篇 |
1992年 | 51篇 |
1991年 | 58篇 |
1990年 | 48篇 |
1989年 | 46篇 |
1988年 | 37篇 |
1987年 | 37篇 |
1986年 | 21篇 |
1985年 | 30篇 |
1984年 | 25篇 |
1983年 | 19篇 |
1982年 | 25篇 |
1981年 | 32篇 |
1980年 | 36篇 |
1979年 | 15篇 |
1978年 | 18篇 |
1975年 | 19篇 |
1973年 | 16篇 |
1972年 | 13篇 |
1968年 | 15篇 |
排序方式: 共有7844条查询结果,搜索用时 0 毫秒
61.
Yoshida M Abe O Uchino J Kikuchi K Abe R Enomoto K Tominaga T Fukami A Sakai K Koyama H Sugimachi K Nomura Y Hattori T Ogawa N 《Breast cancer (Tokyo, Japan)》1997,4(2):103-113
A multi-center, randomized controlled collaborative study was conducted in 310 institutions located throughout Japan for 3 years and 9 months from February 1985 until October 1988 to evaluate the efficacy of post-operative adjuvant therapy for patients who had previously undergone curative surgery for treatment of Stage IIIa breast cancer. Patients with estrogen receptor-positive [ER( + )] breast cancer were treated with two types of regimens, ie, cyclophosphamide + adriamycin + fluorouracil (CAF; 2 cycles) + Futraful (FT) or CAF (2 cycles) + FT + tamoxifen (TAM), and the clinical benefit of additional use of TAM was evaluated. Of the 509 ER( + ) patients registered for the trial, 473 patients (92.9%) were eligible for evaluation. The 5-year survival rate was 77.2% for the CAF + FT group and 74.6% for the CAF + FT+TAM group, and the 5-year disease-free survival rate was 56.7% for the CAF+FT group and 59.2% for the CAF + FT + TAM group. Neither the survival rate nor the disease-free survival rate differed significantly between the groups. Analyses by factor revealed that the 5-year disease-free rate for lymph node-negative patients in the CAF + FT + TAM group was significantly higher than that for the corresponding patients in the CAF + FT group. No differences were noted in the incidence of adverse reactions between the two treatment groups, other than an increase in LDH (the frequency of which was higher in the CAF + FT+TAM group than in the CAF + FT group). Patients with estrogen receptor-negative [ER( -)] breast cancer were treated with two types of regimens, ie, CAF + FT or CAF + FT + adriamycin (ADR), and the clinical benefit of the combined use of intermittent doses of ADR was evaluated. Of the 514 ER(-) patients registered in the trial, 478 (93.0%) were eligible for evaluation. The 5-year survival rate was 64.9% for the CAF + FT group and 63.0% for the CAF + FT + ADR group, and the 5-year disease-free survival rate was 59.2% for both CAF + FT and CAF + FT + ADR groups. Neither the survival rate nor the disease-free survival rate differed significantly between the groups. There were no significant differences between these groups in analyses by nodal or menopausal status. The incidences of adverse reactions including anorexia, nausea/vomiting and alopecia were higher in the CAF + FT+ADR group than in the CAF + FT group. 相似文献
62.
Saeki Toshiaki; Salomon David S.; Johnson Gibbes R.; Gullick Willium J.; Mandai Koichi; Yamagam Keitaro; Moriwaki Shosuke; Tanada Minoru; Takashima Shigemitsu; Tahara Eiichi 《Japanese journal of clinical oncology》1995,25(6):240-249
The frequency of expression and localization of cripto-1 (CR-1),amphiregulin (AR), transforming growth factor alpha (TGF), epidermalgrowth factor receptor (EGFR) and erbB-2 were examined by immunohistochemistryin 45 carcinomas and adjacent non-involved normal colon mucosa.Thirty (66.7%), 24 (53.3%), 23 (51.1%), 23 (51.1%) and 13 (28.9%)of the 45 carcinomas showed positive staining for CR-1, AR,TGF, EGFR and erbB-2, respectively, whereas 7 (15.5%), 17 (37.7%),15 (33.3%), 20 (44.4%) and 0 (0%) of the corresponding non-involvednormal mucosa specimens were reactive. Among 13 carcinomas withlymph node involvement, 10 (76.9%), 8 (61.5%), 10 (76.9%), 8(61.5%) and 7 (53.8%) exhibited positive staining for CR-1,AR, TGF-, EGFR and erbB-2, respectively. There was a statisticallysignificant association between the frequency of either TGF(P<0.05) or erbB-2 (P<0.05) expression and lymph nodemetastasis. In addition, a signficantly higher frequency ofpositive staining for TGF was observedin Dukes' grade C carcinomas(P<0.05). Finally, significant trends for coexpression ofEGFR and either TGF (P<0.01) or AR (P<0.05) were detectedin carcinomas. These data suggest that AR and TGF may play animportant role in the development of colorectal carcinomas throughan autocrine mechanism involving EGFR, and demonstrate thatTGF and erbB-2 may be more reliable indicators of metastasisor prognosis than CR-1, AR or EGFR in human colon cancers. 相似文献
63.
64.
(Received for publication on Oct. 6, 1997; accepted on July 7, 1998) 相似文献
65.
Noriyuki Masuda Shunichi Negoro Kouji Takeda Nobuhide Takifuji Tomonori Hirashima Takashi Yana Noriaki Kurata Takashi Kuwabara Satoshi Kobayashi Shinzoh Kudoh Kaoru Matsui Minoru Takada Masahiro Fukuoka 《Investigational new drugs》1999,16(3):245-254
(E)-2-deoxy-2-(fluoromethylene)cytidine (FMdC), one of the most potent inhibitors of ribonucleoside diphosphate reductase, was selected for clinical development because of its novel mechanisms of action, and strong antitumor activity against experimental tumor models. This study was designed to determine the toxicities, maximum-tolerated dose (MTD), and pharmacokinetic profile of FMdC. FMdC was given orally for 5 consecutive days every 3 or 4 weeks in patients with advanced solid tumors. The starting dose was 8 mg/m2/day. Pharmacokinetic studies were carried out on days 1 through 5 of the first cycle. Ten patients with non-small cell lung cancer received 15 courses of FMdC at doses which were de-escalated from 8 mg/m2/day to 2 mg/m2/day because of unexpected severe toxicities at the starting dose level. Neutropenia was the dose-limiting toxicity. Thrombocytopenia and anemia were mild. Flu-like symptoms and fever were the common non-hematologic toxicities. The MTD was 4 mg/m2/day, since four of six patients developed grade 3–4 neutropenia. At the 4 mg/m2/day dose level, the mean terminal half-life, maximum plasma concentration (Cmax), plasma clearance, and mean residence time on day 1 were 3.20 h, 15.8 ng/ml, 2.91 l/h/kg, and 4.03 h, respectively. The recommended dose for phase II studies with this schedule is also 4 mg/m2/day for 5 days. Further investigations are necessary to establish optimal dosing schedules and routes for the administration of FMdC. 相似文献
66.
Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. 总被引:3,自引:0,他引:3
67.
Shigemi Onoue Takehito Katoh Yoshihisa Shibata Yasushi Mokuno Katsushi Yoshida Satoshi Kamiya Tetsuya Abe Kiyoshi Hiramatsu Minoru Esaki Haruhiko Chigira 《International journal of clinical oncology / Japan Society of Clinical Oncology》1997,2(2):121-124
We report a case of a long-term survivor with malignant melanoma of the anus who did not undergo radical surgery. A 71-year-old
woman who presented with anal bleeding and anal tumor underwent an excisional biopsy in September 1985. The biopsy specimen
was a lobulated, polypoid, pigmented mass 2 cm in diameter, that had been located on the anterior wall of the anus. A satellite
nodule 7 mm in diameter was found on the left wall of the anus at the level of the dentate line. Both tumors were histologically
diagnosed as malignant melanoma. The primary tumor was 6 mm thick. Melanoma cells were present microscopically at the cut
end of the rectum. Because of her history of ischemic heart disease, the patient rejected our recommendation that she undergo
radical surgery, and received 10 courses of carboplatin 20 mg intramuscularly and OK-432 10 K.E. (Klinische Einheit) intradermally
every week. A single, pigmented metastatic inguinal lymph node developed and was excised in June 1987. A recurrent tumor was
detected in the rectum in October 1992, so again we recommended radical surgery. The patient rejected radical surgery again,
and received 12 courses of carboplatin 10 mg intramuscularly every 2 weeks. She died of disease at home in July 1993 after
surviving for 7 years and 10 months. An autopsy was not performed. This case shows that local excision of the primary lesion
may be appropriate to preserve the quality of life of patients with early-stage malignant melanoma of the anus. 相似文献
68.
Hisayuki Hiraiwa Minoru Hamazaki Satoru Tsuruta Hiroyoshi Hattori Jun-Ichi Mimaya Shirou Hasegawa Sumio Kohno Katsuhiko Aoki 《Pediatrics international》1998,40(6):604-607
Infantile hemangioendothelioma of the thymus is a rare disease. We describe a patient who developed a large anterior mediastinal mass, severe thrombocytopenia and massive pleural effusion at 1 month of age. Glucocorticosteroid and irradiation therapy had no effect on either the tumor size or clinical symptoms and the tumor was resected subtotally. Three months after the subtotal resection, the remaining tumor had almost disappeared and the symptoms had resolved. The patient has now been well for 1 year after surgery without evidence of recurrence. The tumor tissue was characterized by prominent vascular endothelial proliferation intermixed with a normal thymic structure, producing a picture consistent with that of an infantile hemangioendothelioma in the thymus, lmmunohistochemically, the tumor cells showed positive staining for vimentin, factor VIII and CD34. The DNA stemline and proliferative activity were examined by flow cytometry, which revealed a diploid stemline with a low growth fraction. DNA content and cell cycle analyses of the tumor tissue may be useful for predicting the biological behavior of the tumor. 相似文献
69.
Ultrasonographic follow-up of the healing process of medically treated hypertrophic pyloric stenosis
In hypertrophic pyloric stenosis (HPS), prompt pyloromyotomy is, in general, the treatment of choice. There has been no information
available as to the natural history of the pyloric tumour. We present four infants with medically treated HPS who were followed
by sonography to observe the anatomical changes that occur with atropine sulfate. The initial change was shortening of the
pyloric canal, followed by thinning of the muscular layer as clinical symptoms improved.
Received: 29 September 1997 Accepted: 3 October 1997 相似文献
70.
Siro Simizu Keiko Tanabe Etsu Tashiro Minoru Takada Kazuo Umezawa Masaya Imoto 《Cancer science》1998,89(9):970-976
In the present study, we found that inostamycin increased the ability of paclitaxel to induce apoptosis in Ms-1 cells. A considerably higher concentration of paclitaxel was required for the induction of apoptosis in Ms-1 cells than in other cell lines tested. Treatment of Ms-1 cells with inostamycin, an inhibitor of phosphatidylinositol (PI) synthesis, reduced the dosage of paclitaxel required to induce cell death by apoptosis. This effect of inostamycin is specific to Ms-1 cells, and inostamycin did not increase the cytotoxicity of other antitumor drugs such as adriamycin, vinblastine, methotrexate, cisplatin, etoposide, or camptothecin in Ms-1 cells. Addition of inostamycin to paclitaxel-treated cells caused a significant increase in the sub G1 peak, representing apoptosis, which was accompanied by a decrease in the G2/M peak seen in paclitaxel-treated Ms-1 cells, without affecting paclitaxel-inhibited tubulin depolymerization. Moreover, paclitaxel did not enhance inostamycin-inhibited PI synthesis. The expression levels of Bcl-2, Bax, and Bcl-XL were not changed following the co-treatment with inostamycin plus paclitaxel, whereas the activated form of caspase-3 was markedly increased. Thus, inostamycin is a chemosensitizer of paclitaxel in small cell lung carcinoma Ms-1 cells. 相似文献